Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks ...

The randomised, double-blind and placebo-controlled trial involved 35 healthy participants, who were each given a single ...

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by ...

Jamie Rauscher, LVT, president of NAVTA, outlined 5 essential steps veterinary technicians should follow for an effective ...

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and ...

Adipo's treatment has the potential to increase energy expenditure by creating healthier, energy-burning, metabolically beneficial subcutaneous fat." The first study examined the effect of ADPO-002 ...